KRAS(G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

PURPOSE: KRAS(G12C) is the most common KRAS mutation in primary lung adenocarcinoma (LUAD). Phase I clinical trials have demonstrated encouraging clinical activity of KRAS(G12C) inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Jones, Gregory D., Caso, Raul, Tan, Kay See, Mastrogiacomo, Brooke, Sanchez-Vega, Francisco, Liu, Yuan, Connolly, James G., Murciano-Goroff, Yonina R., Bott, Matthew J., Adusumilli, Prasad S., Molena, Daniela, Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Misale, Sandra, Yaeger, Rona, Drilon, Alexander, Arbour, Kathryn C., Riely, Gregory J., Rosen, Neal, Lito, Piro, Zhang, Haiying, Lyden, David C., Rudin, Charles M., Jones, David R., Li, Bob T., Isbell, James M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102372/
https://ncbi.nlm.nih.gov/pubmed/33593884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4772
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы